- About Us
- PCRS-UK Community
- PCRS-UK Committees and Trustees
- PCRS-UK Trustees
- PCRS-UK Executive
- PCRS-UK Education Committee
- PCRS-UK Conference Organising Committee
- PCRS-UK Service Development Committee
- Primary Care Respiratory Update Editorial Board
- Respiratory Leaders Programme Board
- PCRS-UK Affiliated Group Leaders Committee
- Policy Forum
- Lay Reference Group
- Interested in joining a committee?
- PCRS-UK Regional Leads
- Clinical Leadership Programme
- Local Groups
- Your questions answered
- Respiratory Researchers
- PCRS-UK Committees and Trustees
- Annual Conference
- Respiratory Leaders Meetings
- Local Group Leaders Events
- Other Meetings
- Early Researchers Meeting
- Contact Us
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit www.astrazeneca.com
Boehringer Ingelheim For more than 130 years, our research-driven pharmaceutical company has created innovative medicines for people and animals. Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies and to this day remains family-owned. Every day, our 50,000 employees create value through innovation in our three business areas: human pharmaceuticals, animal health and biopharmaceutical contract manufacturing Social responsibility comes naturally to Boehringer Ingelheim. That’s why we are involved in social projects such as the “Making More Health” initiative. Boehringer Ingelheim also actively promotes workforce diversity and benefits from our employees’ different experiences and skills. Environmental protection and sustainability is the focus of everything we do. More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.
Chiesi Limited is the UK affiliate of Chiesi Farmaceutici S.p.A. It is headquartered in Manchester and employs over 250 employees. Chiesi Farmaceutici is an international research-focussed Healthcare Group based in Parma, Italy, with over 80 years of experience in the pharmaceutical industry. The group employs nearly 5,000 people and has affiliates in 26 countries, with its products reaching over 70 countries. Chiesi researches, develops and markets innovative drugs in the respiratory therapeutics, specialist medicine and rare disease areas. Its R&D organisation is also headquartered in Parma, Italy, and integrated with six other key R&D groups in France, the USA, the UK, Sweden and Denmark to advance Chiesi's pre-clinical, clinical and registration programmes. R&D remains a key priority for Chiesi, with the product pipeline increasingly leveraging novel, proprietary therapeutics that target diseases with high unmet medical need, with the ultimate aim of giving patients access to innovative medicines that improve quality of life.
Napp Pharmaceuticals Limited is a UK healthcare company with a strong track record in bringing high-quality, innovative medicines to UK health professionals and their patients. We are a committed long-term NHS provider in respiratory medicine, supporting the delivery of real-world evidence and education. We aim to provide high-quality asthma medicines that meet genuine needs, make a positive difference to patients’ lives and offer value to the NHS.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. Novartis Group companies employ approximately 119,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. For more information, please visit http://www.novartis.co.uk
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines. Our diversified global healthcare portfolio includes biologic and small molecule medicines and vaccines, as well as many of the world’s best-known consumer products. Every day, Pfizer colleagues work to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. Please visit the Pfizer stand to hear more about smoking cessation and the Pfizer alliances with Novartis and Bristol-Myers Squibb and how we collaborate to improve the wellbeing of patients living with COPD and cardiovascular disease in the United Kingdom.